Table 1.

Sensitivities of 34 tumor-derived cell lines

Cell lineTissue of originLapatinib IC50 (μmol/L) ± SE
Training setBT474Breast0.025 ± 0.004
NCI-N87Gastric0.028 ± 0.002
HN5Head/neck0.029 ± 0.005
SKBr3Breast0.032 ± 0.005
MDA-MB-453Breast0.079 ± 0.025
A431Skin, epidermoid0.23 ± 0.06
NCI-H322Lung0.92 ± 0.02
BxPC3Pancreatic1.41 ± 0.13
SKOV3 ATCCOvarian1.25 ± 0.11
786ORenal1.82 ± 0.17
MDA-MB-468Breast2.32 ± 0.21
DLD-1Colon3.63 ± 0.86
LNCaPProstate4.69 ± 0.52
MCF7Breast4.82 ± 1.14
T47DBreast4.83 ± 1.12
A549Lung4.98 ± 0.49
HT-29Colon5.24 ± 1.01
RKOColon5.48 ± 0.52
MX1Breast5.55 ± 1.55
HCT 116Colon5.87 ± 2.04
SKMEL28Melanoma5.90 ± 0.37
MDA-MB-231Breast7.01 ± 0.51
PC3Prostate7.15 ± 2.24
Colo 205Colon7.70 ± 1.03
Validation setSCC-15Head/neck0.171 ± 0.003
FaDuHead/neck0.216 ± 0.025
SCC-25Head/neck0.222 ± 0.065
CAL-27Head/neck0.308 ± 0.107
SCC-9Head/neck0.331 ± 0.084
SCC-12Head/neck0.674 ± 0.059
SCC-13Head/neck1.063 ± 0.196
SCC-4Head/neck1.851 ± 0.387
RPMI2650Head/neck2.931
SW579Head/neck3.074 ± 0.277
  • NOTE: This includes both predictive model training and validation cell line panels.